Our recognition
Latest stories
Featured
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
- Hikma to host meet the management and site visit in Columbus, Ohio Press Release, Corporate 17 March 2025 Hikma to host meet the management and site visit in Columbus, Ohio
- Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US Press Release, Product 27 February 2025 Hikma receives FDA approval and launches Mercaptopurine Oral Suspension in the US
- Strong 2024 performance and a positive outlook for 2025 Press Release, Financial Results 26 February 2025 Strong 2024 performance and a positive outlook for 2025
- Notice of results Press Release, Financial Results 10 February 2025 Notice of results
Related content